Epidermolysis Bullosa Clinical Trial Pipeline Robust as 20+ Companies Advance 21+ Gene and Cell Therapies Toward Market Entry, Finds DelveInsight | Abeona Therapeutics, Krystal Biotech, Chiesi, Phoenicis Therapeutics, Aegle Therapeutics, RegeneRx Biopharm

DelveInsight's "Epidermolysis Bullosa - Pipeline Insight, 2026" report provides comprehensive insights about 20+ companies developing 21+ pipeline drugs in the Epidermolysis Bullosa pipeline landscape. It covers the Epidermolysis Bullosa pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Epidermolysis Bullosa treatment landscape. Learn more about the evolving pipeline Epidermolysis Bullosa @ https://www.delveinsight.com/report-store/epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
​
Key Takeaways from the Epidermolysis Bullosa Pipeline Report

• In September 2025, the FDA approved label expansion for Krystal Biotech's VYJUVEK (B-VEC, beremagene geperpavec-svdt), extending use to DEB patients from birth with at-home application and flexible dressing removal.
• In May 2025, RELIEF THERAPEUTICS received FDA Rare Pediatric Disease Designation (RPDD) for RLF-TD011 in EB, following prior Orphan Drug Designation.
• IN May 2025, DEBRA Research and Dermaliq Therapeutics formed a strategic collaboration, including investment, to develop topical therapies for EB wound healing, itch relief, and prophylaxis using hyliQ technology.
• In April 2025, the FDA approved ZEVASKYN (prademagene zamikeracel, pz-cel) by Abeona Therapeutics, the first autologous cell-based gene therapy for wounds in RDEB patients.
• The leading Epidermolysis Bullosa companies include Abeona Therapeutics, InMed Pharmaceuticals, BioMendics, RHEACELL, Castle Creek Biosciences, BPGbio, Eloxx Pharmaceuticals, Phoenicis Therapeutics, Aegle Therapeutics, Amryt Pharma, Krystal Biotech, Chiesi, RegeneRx Biopharmaceuticals, BridgeBio Pharma, Holostem Terapie Avanzate, Anterogen Co., Ltd., Fibrocell Science, and others.
• Promising Epidermolysis Bullosa therapies include BPM31510, HOLOGENE-17, AGLE102, RGN-137, PTR-01, INM-755, Dabocemagene autoficel, VYJUVEK, EB-101, FCX-007, SD-101-6.0 cream, ALLO-ASC-SHEET, PTW-002 10 mg/g gel, and others targeting COL7A1 restoration, wound healing, and inflammation modulation across EB subtypes.

Download for Epidermolysis Bullosa recent updates and evolving trends @ https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Epidermolysis Bullosa Emerging Drugs Profile

• EB-101: Abeona Therapeutics
EB-101 (pz-cel) is an autologous cell therapy consisting of genetically corrected keratinocyte sheets engineered from the patient's own skin cells to express functional type VII collagen (COL7), addressing the root cause of dystrophic epidermolysis bullosa (DEB). Applied surgically as a single treatment to chronic wounds, EB-101 promotes durable wound closure, reduces blistering, and alleviates pain by restoring anchoring fibrils at the dermal-epidermal junction. FDA approval was supported by pivotal Phase 3 VIITAL trial results demonstrating statistically significant ≥50% large chronic wound healing and Wong‐Baker FACES pain scale improvement at six months, marking it as a transformative ex vivo gene therapy for recessive DEB.

• AGLE102: Aegle Therapeutics
AGLE102 is a first‐in‐class allogeneic mesenchymal stem cell (MSC) therapy derived from induced pluripotent stem cells (iPSCs), designed for topical application to promote wound healing and reduce inflammation in epidermolysis bullosa wounds. By secreting growth factors, extracellular vesicles, and anti‐inflammatory cytokines, AGLE102 accelerates re‐epithelialization, minimizes scarring, and improves skin integrity without genetic modification. Currently in Phase 2 development, AGLE102 represents a scalable, off‐the‐shelf regenerative approach highlighted by DelveInsight for its potential to address unmet needs in both DEB and junctional EB subtypes.

For more information on the Epidermolysis Bullosa Emerging Drugs Profile, download DelveInsight's comprehensive Epidermolysis Bullosa Pipeline Insight report. @ https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

The Epidermolysis Bullosa Pipeline Report Provides

• Detailed insights about companies developing therapies for Epidermolysis Bullosa, with aggregate therapies developed by each company.
• Different therapeutic candidates, segmented into early‐stage, mid‐stage, and late‐stage of development for Epidermolysis Bullosa treatment.
• Epidermolysis Bullosa companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Epidermolysis Bullosa drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company and company-academia), licensing agreements, and financing details for future advancement of the Epidermolysis Bullosa market.

Learn more about Epidermolysis Bullosa drugs opportunities in our groundbreaking research and development projects @ https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Epidermolysis Bullosa Companies

There are 20+ key companies developing therapies for Epidermolysis Bullosa, such as Abeona Therapeutics, Krystal Biotech, Chiesi, Phoenicis Therapeutics, Aegle Therapeutics, RegeneRx Biopharmaceuticals, BridgeBio Pharma, InMed Pharmaceuticals, Fibrocell Science, Holostem Terapie Avanzate, Anterogen Co., Ltd., Castle Creek Biosciences, and others.

DelveInsight's Epidermolysis Bullosa pipeline report notes that Abeona Therapeutics holds one of the most advanced gene‐corrected cell therapy assets with recent FDA approval, while topical and allogeneic stem cell programs from Aegle, Krystal Biotech, and others populate the late‐ and mid‐stage pipeline.

DelveInsight's Epidermolysis Bullosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Epidermolysis Bullosa products have been categorized under various Molecule types such as:

• Monoclonal antibody
• Small molecule
• Peptide

Scope of the Epidermolysis Bullosa Pipeline Report

• Coverage: Global
• Epidermolysis Bullosa companies: Abeona Therapeutics, InMed Pharmaceuticals, BioMendics, RHEACELL, Castle Creek Biosciences, BPGbio, Eloxx Pharmaceuticals, Phoenicis Therapeutics, Aegle Therapeutics, Amryt Pharma and others
• Epidermolysis Bullosa Therapies: BPM31510, HOLOGENE-17, AGLE102, RGN-137, PTR-01, INM-755, Dabocemagene autoficel, VYJUVEK, and others
• Epidermolysis Bullosa Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Epidermolysis Bullosa Therapeutic Assessment by Clinical Stages: Discovery, Pre‐clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings, read the full details of the Epidermolysis Bullosa Pipeline @ https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a leading healthcare‐focused market research and consulting firm that provides clients with high‐quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, DelveInsight offers customized research solutions and insights to clients across the globe, helping them stay ahead of the growth curve.

This release was published on openPR.